Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-FAPI-RGD PET/CT in Lung Cancer
NCT05543954Phase 1Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2022
- Primary completion
- Dec 2025
- Modality
- Radiopharmaceutical, Diagnostic Agent, CA (Contrast Agent)
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-LNC1007 in lung cancer, sponsored by Peking Union Medical College Hospital. Primary endpoint: Diagnostic performance at 1 year. Started Sep 2022; status: recruiting.
02
Drugs
68Ga-LNC1007
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT05543954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05543954.